Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Biol Hung ; 52(1): 179-85, 2001.
Article in English | MEDLINE | ID: mdl-11396838

ABSTRACT

Lemna minor is a species easy to collect and culture in laboratory, and can give rapid test results. However, in order to standardise toxicity tests using Lemna minor as test organism, it is important to find out what natural variability different populations might have. Five Lemna populations were used for comparison. It contained two standard cultures and three populations collected in natural habitats. Potassium dichromate was applied as test material. Lemna populations cultured under the same conditions showed different T(D) and LC50 values. There is an inverse relation between the sensitivity and T(D) of the strains. It is supposed that growth rate and sensitivity of Lemna populations depend on environmental factors characterising the habitat in which the given popluation originally lives.


Subject(s)
Magnoliopsida/drug effects , Toxicity Tests/standards , Reproducibility of Results
2.
Arterioscler Thromb Vasc Biol ; 17(11): 2861-7, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9409267

ABSTRACT

On the basis of an array of preclinical experimental results, it has been widely assumed that endothelin-1 (ET-1) may affect blood coagulation, fibrinolysis, and endothelial cell function, thereby playing a pathophysiological role in various cardiovascular diseases in humans. However, confirmation of this assumption is still lacking. ET-1 or placebo was administered intravenously to 12 healthy volunteers in a prospective, randomized, double-blind, crossover trial. Pathophysiologically relevant concentrations of ET-1 (an approximate threefold increase of normal blood levels) causing hemodynamic effects were reached by continuous intravenous infusion for 6 hours. Components of the coagulation (thrombin-antithrombin complexes, prothrombin fragment F1 + 2, activated factor VII, and factor VII antigen) and fibrinolytic (fibrin split product D-dimer, plasmin-plasmin inhibitor complex, tissue-type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1) systems and markers of endothelial cell perturbation/dysfunction (von Willebrand factor and thrombomodulin) were measured before the start of infusion and after 2, 6, 12, and 24 hours. Comparing changes in the plasma concentrations of these parameters during and after infusion of ET-1 and placebo, we found no specific effects of ET-1. In contrast to previous reports from preclinical experiments, ET-1 does not appear to affect coagulation or fibrinolysis, nor does this peptide induce relevant endothelial cell perturbations in humans.


Subject(s)
Blood Coagulation/drug effects , Endothelin-1/pharmacology , Endothelium, Vascular/drug effects , Fibrinolysis/drug effects , Hemodynamics/drug effects , Adult , Cross-Over Studies , Double-Blind Method , Hemoglobins/analysis , Humans , Insulin/blood , Male , Pilot Projects , Plasminogen Activator Inhibitor 1/blood , Prospective Studies , Renal Circulation/drug effects , Tissue Plasminogen Activator/blood , Urokinase-Type Plasminogen Activator/blood , p-Aminohippuric Acid/blood , von Willebrand Factor/analysis
3.
Eur J Clin Invest ; 27(10): 850-6, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9373765

ABSTRACT

Several studies point to a role for endothelin-1 (ET-1) in enhancing adhesion molecule expression and leucocyte adhesion. We thus hypothesized that ET-1 would induce expression of adhesion molecules by endothelial cells and by leucocytes in humans, and hence compared with placebo the effect of a continuous 6-h ET-1 infusion on plasma levels of circulating (c)E-selectin, cP-selectin, intercellular and vascular cell adhesion molecule 1. In addition, we investigated the effects of ET-1 on expression of the leucocyte adhesion molecules CD11b/CD18 and L-selectin on monocytes and neutrophils. After an open pilot study to evaluate the safety of a 6-h ET-1 infusion of 0.4 pmol kg-1 min-1 (n = 4), the main study was conducted as a randomized, double-blind, two-way, cross-over trial in 12 additional young healthy male volunteers, who received the same treatment and were observed over a period of 24 h. ET-1 infusion decreased renal plasma flow by 43% (CI 35-51%; P < 0.001) and increased the filtration fraction by 80% (CI 20-110%; P < 0.001). Heart rate decreased by -10% (CI -4% to -15%) at 6 h under ET-1 infusion in the cross-over trial (P = 0.012 between periods). Although ET-1 infusions increased plasma levels of ET-1 by about 300%, ET-1 elicited no relevant changes in any circulating adhesion molecules or leucocyte adhesion molecules measured. In the placebo period small diurnal changes were observed for cP-selectin (-8%, CI -14 to -3%, P = 0.008) and cE-selectin (-6%, CI -10 to -3%, P = 0.003) at 12 h (20.45 h). In sum, ET-1 does not regulate circulating adhesion molecules in healthy men. Circadian variations may exist for plasma levels of cP-selectin and cE-selectin.


Subject(s)
Cell Adhesion Molecules/blood , Endothelin-1/pharmacology , Adult , CD11 Antigens/analysis , CD18 Antigens/analysis , Cross-Over Studies , Double-Blind Method , Endothelin-1/blood , Hemodynamics/drug effects , Humans , Intercellular Adhesion Molecule-1/blood , Male , Pilot Projects , Vascular Cell Adhesion Molecule-1/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...